IPO Timeline
Broker Results (T-2)
2020-12-08
Some brokers release in afternoon
Grey Market (T-1)
2020-12-09
Afternoon
HKEX Allotment (T-1)
2020-12-09
Evening
Registrar Allotment (T-1)
2020-12-09
Evening
Listing Day (T)
2020-12-10
First day of trading
Company Overview
| Stock Name | 和鉑醫藥控股有限公司 -B |
|---|---|
| Stock Code | 02142 |
| Company Full Name | 和鉑醫藥控股有限公司 -B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注研究及開發免疫與腫瘤疾病領域的抗體療法。 |
| Listing Date | 2020-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市徐匯區楓林路420號楓林國際大廈二期A座12樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.harbourbiomed.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.38 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 41.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 684,490,200 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 11.02 |
|---|---|
| First Day Open | HK$ 11.94 |
| First Day Change | -10.99% |
| First Day Volume | 57898000.0 |
| First Day Turnover | 695749000.0 |
Use of Proceeds
| Use of Proceeds | 1、約591.5百萬港元（占37%）預期將用于撥資我們的核心產品； 2、約367.7百萬港元（占23%）預期將用于撥資我們的支柱資產HBM4003在大中華區及澳洲的進行中及計劃進行的臨床試驗、籌備在大中華區、美國及其他司法權區的注冊備案及潛在商業化推出； 3、約239.8百萬港元（占15%）預期將用于撥資我們其他正在尋求IND批準及尚未開始臨床試驗或臨床前研究的候選藥物的研發； 4、約191.9百萬港元（占12%）預期將用于撥資和鉑抗體平臺產生的創新型分子發現； 5、約79.9百萬港元（占5%）預期將用于撥資持續改進平臺技術、利用和鉑抗體平臺尋求授權及合作機會； 6、約127.9百萬港元（占8%）預期將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
摩根士丹利亚洲有限公司 CE AAD291
Merrill Lynch (Asia Pacific) Limited CE AAC198
中信证券（香港）有限公司 CE AAK249
Overall Coordinators (5)
摩根士丹利亚洲有限公司 CE AAD291
Merrill Lynch (Asia Pacific) Limited CE AAC198
中信里昂证券有限公司 CE AAB893
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (7)
摩根士丹利亚洲有限公司 CE AAD291
Merrill Lynch (Asia Pacific) Limited CE AAC198
中信里昂证券有限公司 CE AAB893
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
海通国际证券有限公司 CE AAF806
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (5)
摩根士丹利亚洲有限公司 CE AAD291
Merrill Lynch (Asia Pacific) Limited CE AAC198
中信里昂证券有限公司 CE AAB893
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 38,761,780 HKD | — | 2.27% | — | 6 months | 2021-06-10 |
| 2 | Anlan Funds | 54,261,540 HKD | — | 3.17% | — | 6 months | 2021-06-10 |
| 3 | BlackRock Funds | 232,595,440 HKD | — | 13.59% | — | 6 months | 2021-06-10 |
| 4 | HBM Healthcare Investments (Cayman) Ltd. | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 5 | Hillhouse Funds | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 6 | Hudson Bay Master Fund LTD | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 7 | LC HEALTHCARE FUND I, L.P. | 38,761,780 HKD | — | 2.27% | — | 6 months | 2021-06-10 |
| 8 | Octagon Investments Master Fund LP | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 9 | OrbiMed Funds | 38,761,780 HKD | — | 2.27% | — | 6 months | 2021-06-10 |
Directors & Management
| Chairman | 王勁松 |
|---|---|
| Company Secretary | 呂穎一,劉毅 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Advantech Capital L.P.(12.18%);君聯資本管理股份有限公司(8.93%);王勁松(7.86%);新加坡政府投資有限公司(6.59%) |
|---|
IPO Timeline
